Orexo is a fully integrated specialty pharmaceutical company which has developed four products from idea to patient.
Products approved worldwide
Our drug delivery technologies improve pharmaceuticals
Partnerships are critical to our success
We will be recognized for the added value our products bring to patients and societies
Orexo’s share is listed on Nasdaq Stockholm Mid Cap and available as American Depository Receipts (ADRs) on OTCQX in the US.
Follow Orexo in social media
AUGUST 2 2017 - CVS Caremark has published their 2018 Exclusion Template Formulary List for their commercial clients. Effective Jan. 1, 2018, Zubsolv will be placed in a preferred parity position with the market-leading product.
JULY 11 2017 - Listen to Nikolaj Sørensen, CEO, and Henrik Juuel, CFO, presenting the Q2 17 Interim Report
JULY 11 2017 - The effort of developing the next generation of our drug delivery technologies has led to a new project, OX382, which is an innovative oral formulation. Clinical phase I studies are planned within the next 6 to 9 months.
Lisa Hastings, Sales Manager, Region West, US. Besides increased sales of Zubsolv®, Lisa hopes that more products will be added to the commercial portfolio.
July 11, 2017 - "Continued strong financial performance"
Analysis | Here's what happens if Trump declares opioid abuse a national emergency https://t.co/NRDFeEtuL5
The US president will held a speach tonight about the #opioidcrisis #opioidaddiction #orexo. Good news. STAY TUNED. https://t.co/b7TQ7X69ig
#opioidcrisis "We have a 9/11-scale loss every 3 weeks" says Christie who wants to declare a Public Health Emergency https://t.co/9FlacRYaR3